

Chronic Disease Fund, Inc. dba Good Days

Financial Statements

December 31, 2024 and 2023



TABLE OF CONTENTS

	<u>Page No.</u>
Independent Auditor's Report	1 - 2
Statements of Financial Position	3
Statements of Activities	4 - 5
Statements of Functional Expenses	6 - 7
Statements of Cash Flows	8
Notes to Financial Statements	9 - 20



INDEPENDENT AUDITOR'S REPORT

Board of Directors
Chronic Disease Fund, Inc. dba Good Days

Opinion

We have audited the accompanying financial statements of Chronic Disease Fund, Inc. dba Good Days (a New Jersey nonprofit corporation), which comprise the statements of financial position as of December 31, 2024 and 2023, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Chronic Disease Fund, Inc. dba Good Days as of December 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Chronic Disease Fund, Inc. dba Good Days and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Chronic Disease Fund, Inc. dba Good Days's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Chronic Disease Fund, Inc. dba Good Days's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Chronic Disease Fund, Inc. dba Good Days's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Armanino LLP

Dallas, Texas

June 13, 2025

Chronic Disease Fund, Inc. dba Good Days
Statements of Financial Position
December 31, 2024 and 2023

	2024	2023
ASSETS		
Cash and cash equivalents	\$ 17,877,342	\$ 65,827,712
Accounts receivable	141,295	243,475
Contributions receivable	1,801,000	12,760,000
Program service receivable	512,865	467,672
Prepaid expenses and other assets	603,168	585,860
Investments, at fair value	194,869,073	137,105,474
Operating lease right-of-use assets	1,500,035	1,797,122
Property and equipment, net	3,329,705	2,708,289
Total assets	\$ 220,634,483	\$ 221,495,604
LIABILITIES AND NET ASSETS		
Liabilities		
Co-pay payable	\$ 20,860,336	\$ 16,126,185
Accounts payable and accrued expenses	738,055	947,145
Deferred revenue	105,300	105,300
Operating lease liabilities	1,698,020	2,004,633
Total liabilities	23,401,711	19,183,263
Net assets		
Without donor restrictions	101,190,709	84,089,900
With donor restrictions	96,042,063	118,222,441
Total net assets	197,232,772	202,312,341
Total liabilities and net assets	\$ 220,634,483	\$ 221,495,604

The accompanying notes are an integral part of these financial statements.

Chronic Disease Fund, Inc. dba Good Days
Statement of Activities
For the Year Ended December 31, 2024

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>
Revenues, gains and other support			
Contributions	\$ 16,915,281	\$ 463,782,025	\$ 480,697,306
Program service income	3,548,242	-	3,548,242
Sponsorships for educational events	76,160	-	76,160
Software licenses and other revenue	449,423	-	449,423
Investment income, net	9,912,352	-	9,912,352
Net assets released from restriction	<u>485,962,403</u>	<u>(485,962,403)</u>	<u>-</u>
Total revenues, gains and other support	<u>516,863,861</u>	<u>(22,180,378)</u>	<u>494,683,483</u>
Functional expenses			
Program services	492,213,204	-	492,213,204
Management and general	6,805,595	-	6,805,595
Fundraising	<u>744,253</u>	<u>-</u>	<u>744,253</u>
Total functional expenses	<u>499,763,052</u>	<u>-</u>	<u>499,763,052</u>
Change in net assets	17,100,809	(22,180,378)	(5,079,569)
Net assets, beginning of year	<u>84,089,900</u>	<u>118,222,441</u>	<u>202,312,341</u>
Net assets, end of year	<u>\$ 101,190,709</u>	<u>\$ 96,042,063</u>	<u>\$ 197,232,772</u>

The accompanying notes are an integral part of these financial statements.

Chronic Disease Fund, Inc. dba Good Days
Statement of Activities
For the Year Ended December 31, 2023

	Without Donor Restrictions	With Donor Restrictions	Total
Revenues, gains and other support			
Contributions	\$ 15,852,040	\$ 432,555,995	\$ 448,408,035
Program service income	3,335,063	-	3,335,063
Sponsorships for educational events	106,095	-	106,095
Software licenses and other revenue	610,214	-	610,214
Investment income, net	6,119,555	-	6,119,555
Net assets released from restriction	<u>399,840,236</u>	<u>(399,840,236)</u>	<u>-</u>
Total revenues, gains and other support	<u>425,863,203</u>	<u>32,715,759</u>	<u>458,578,962</u>
Functional expenses			
Program services	405,677,228	-	405,677,228
Management and general	6,724,998	-	6,724,998
Fundraising	<u>761,933</u>	<u>-</u>	<u>761,933</u>
Total functional expenses	<u>413,164,159</u>	<u>-</u>	<u>413,164,159</u>
Change in net assets	12,699,044	32,715,759	45,414,803
Net assets, beginning of year	<u>71,390,856</u>	<u>85,506,682</u>	<u>156,897,538</u>
Net assets, end of year	<u>\$ 84,089,900</u>	<u>\$ 118,222,441</u>	<u>\$ 202,312,341</u>

The accompanying notes are an integral part of these financial statements.

Chronic Disease Fund, Inc. dba Good Days
Statement of Functional Expenses
For the Year Ended December 31, 2024

	<u>Program Services</u>	<u>Management and General</u>	<u>Fundraising</u>	<u>Total</u>
Assistance expenses	\$ 485,964,883	\$ -	\$ -	\$ 485,964,883
Salaries and wages	3,097,907	1,359,851	205,657	4,663,415
Payroll taxes	923,672	405,454	61,319	1,390,445
Legal fees	-	2,448,345	6,844	2,455,189
Professional services	134,131	578,090	32,437	744,658
Community and education	625,255	-	-	625,255
Advertising	-	-	33,196	33,196
Office expenses	-	52,584	-	52,584
Information technology	543,430	543,430	120,762	1,207,622
Rent and utilities	223,340	223,340	49,631	496,311
Meals, entertainment and travel	33,742	89,978	101,226	224,946
Conferences	334,547	529,701	65,051	929,299
Insurance	-	188,979	20,998	209,977
Printing and processing	124,950	24,500	2,722	152,172
Telephone and internet	151,182	151,182	33,596	335,960
Miscellaneous	7,502	161,498	-	169,000
Depreciation and amortization	48,663	48,663	10,814	108,140
	<u>\$ 492,213,204</u>	<u>\$ 6,805,595</u>	<u>\$ 744,253</u>	<u>\$ 499,763,052</u>

The accompanying notes are an integral part of these financial statements.

Chronic Disease Fund, Inc. dba Good Days
Statement of Functional Expenses
For the Year Ended December 31, 2023

	Program Services	Management and General	Fundraising	Total
Assistance expenses	\$ 399,872,030	\$ -	\$ -	\$ 399,872,030
Salaries and wages	2,785,808	1,462,253	221,239	4,469,300
Payroll taxes	871,878	457,644	69,242	1,398,764
Legal fees	-	2,025,888	6,851	2,032,739
Compliance	-	286,784	-	286,784
Professional services	134,823	532,836	34,358	702,017
Community and education	554,137	-	-	554,137
Advertising	-	-	23,769	23,769
Office expenses	-	53,443	-	53,443
Information technology	514,745	514,745	114,389	1,143,879
Rent and utilities	221,964	221,964	49,322	493,250
Meals, entertainment and travel	35,139	93,704	105,416	234,259
Conferences	331,634	525,088	64,485	921,207
Insurance	-	185,782	20,643	206,425
Printing and processing	124,950	24,749	2,749	152,448
Telephone and internet	164,255	164,255	36,500	365,010
Miscellaneous	7,502	117,500	-	125,002
Depreciation and amortization	58,363	58,363	12,970	129,696
	<u>\$ 405,677,228</u>	<u>\$ 6,724,998</u>	<u>\$ 761,933</u>	<u>\$ 413,164,159</u>

The accompanying notes are an integral part of these financial statements.

Chronic Disease Fund, Inc. dba Good Days
 Statements of Cash Flows
 For the Years Ended December 31, 2024 and 2023

	2024	2023
Cash flows from operating activities		
Change in net assets	\$ (5,079,569)	\$ 45,414,803
Adjustments to reconcile change in net assets to net cash provided by operating activities		
Depreciation and amortization	108,140	129,696
Net realized and unrealized gains on investments	(1,238,215)	(1,290,651)
Changes in operating assets and liabilities		
Accounts receivable	102,180	(53,343)
Contributions receivable	10,959,000	(4,704,500)
Program service receivable	(45,193)	(13,890)
Prepaid expenses and other assets	(17,308)	(96,737)
Operating lease right-of-use assets	297,087	290,385
Co-pay payable	4,734,151	3,078,318
Accounts payable and accrued expenses	(256,432)	(477,898)
Deferred revenue	-	(11,000)
Operating lease liabilities	(306,613)	(288,565)
Net cash provided by operating activities	9,257,228	41,976,618
Cash flows from investing activities		
Purchases of investments	(219,525,384)	(138,457,459)
Proceeds from sales of investments	163,000,000	38,625,884
Purchases of property and equipment	(682,214)	(723,806)
Net cash used in investing activities	(57,207,598)	(100,555,381)
Net decrease in cash and cash equivalents	(47,950,370)	(58,578,763)
Cash and cash equivalents, beginning of year	65,827,712	124,406,475
Cash and cash equivalents, end of year	\$ 17,877,342	\$ 65,827,712

Supplemental schedule of noncash investing and financing activities

Operating lease right-of-use asset obtained in exchange for operating lease liability	\$ -	\$ 32,645
Property and equipment additions included in accounts payable and accrued expenses	\$ 47,342	\$ -

The accompanying notes are an integral part of these financial statements.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

1. NATURE OF OPERATIONS

Chronic Disease Fund, Inc. dba Good Days (the "Organization") is a nonprofit organization located in Frisco, Texas. The Organization was incorporated under the laws of the state of New Jersey in October 2003. The Organization's goal is to improve the health and quality of life of qualifying individuals who are diagnosed with a chronic or life altering disease by providing co-pay, premium and/or travel assistance ("assistance expenses").

The Organization receives donations from individuals and corporations to assist with prescription co-pays, insurance premiums and travel for specific disease states. The Organization uses a multiple of Federal Poverty Level in calculating financial guidelines and has received an approved Office of Inspector General Advisory Opinion (06-10 and 09-04) for its programs. The Organization does not allocate more than 7% of contributions received to cover administrative costs.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of accounting and financial statement presentation

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Net assets and changes therein are classified as follows:

- *Net assets without donor restrictions* - Net assets available for use in general operations and not subject to donor-imposed stipulations. Net assets without donor restrictions may be designated for specific purposes by action of the Board of Directors. The Organization had no board-designated net assets as of December 31, 2024 or 2023.
- *Net assets with donor restrictions* - Net assets subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both. The Organization had no permanently restricted net assets as of December 31, 2024 or 2023.

Revenues are reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on assets and liabilities are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law. Expirations of net assets with donor restrictions (i.e., the donor-stipulated purpose has been fulfilled or the stipulated time period has elapsed) are reported as reclassifications between the applicable classes of net assets.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Use of estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Uses of estimates include, but are not limited to, the accounting for the allowance for expected credit losses ("AECL") for accounts receivable and program service receivable, the allowance for doubtful contributions receivable, the estimated useful lives of property and equipment and the allocation of expenses by function. Actual results could differ from those estimates.

Cash and cash equivalents

The Organization considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. At December 31, 2024 and 2023, cash equivalents consisted primarily of money market accounts with brokers. Cash held temporarily for reinvestment is included with investments in the accompanying financial statements.

The Organization maintains its cash and cash equivalents at financial institutions with demonstrated financial strength, which, at times, exceeds federally insured limits. The Organization has not incurred any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

Accounts receivable

Accounts receivable consists of software licenses and other revenue due to the Organization as of December 31, 2024. The Organization uses the allowance method to account for software licenses and other revenue. The AECL related to accounts receivable is based on historical collection experience and expectations of future cash flows based on the evaluation of the outstanding receivables at the end of the year. Bad debt recoveries are included in income as realized. Management has determined that no AECL for accounts receivable was necessary at December 31, 2024 or 2023.

Investments, at fair value

Investments are recorded at fair value. Investment income, net includes dividends, interest and realized and unrealized gains and losses less external investment expenses on investments carried at fair value.

Investment income, net is reflected in the statements of activities as with or without donor restrictions based upon the existence and nature of any donor or legally imposed restrictions.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Investments, at fair value (continued)

Investments are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investments, it is at least reasonably possible that changes in the values of the investments will occur in the near term and that such changes could materially affect the amounts reported in the statements of financial position.

Fair value measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. U.S. GAAP requires the Organization to disclose assets and liabilities measured at fair value based on the level of observable inputs. The three levels of the fair value hierarchy are as follows:

- *Level 1* - Quoted prices in active markets for identical assets or liabilities. An active market is a market in which transactions occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
- *Level 2* - Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
- *Level 3* - Unobservable inputs that are supported by little or no market activity, are significant to the fair value of the assets and liabilities and reflect management's assumptions and best estimates based on available data.

The Organization holds fixed income investments in various bonds that are reported using Level 2 inputs and consist primarily of investment grade instruments issued by corporations. The fair value of the bonds is measured on a recurring basis based on observable inputs such as quoted market prices for similar instruments, yield to maturity, credit ratings, and interest rate curves.

Valuation techniques used in fair value measurements need to maximize the use of observable inputs and minimize the use of unobservable inputs. A valuation method may produce a fair value measurement that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes the valuation methods are appropriate and consistent with those used by other market participants, the use of different methodologies or assumptions could result in different fair value measurements at the reporting date. There have been no significant changes in valuation techniques during the years ended December 31, 2024 or 2023.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Leases

The Organization leases postage and mailing equipment as well as office space. The Organization determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use ("ROU") assets and operating lease liabilities.

ROU assets represent the Organization's right to use an underlying asset for the lease term and lease liabilities represent its obligations to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. For the initial measurement of lease liabilities, the discount rate that the Organization uses is either the rate implicit in the lease, if known, or risk-free rate with a similar term to the lease. The Organization recognizes lease expense for all operating leases on a straight-line basis over the lease term. The Organization's lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Organization has elected not to recognize ROU assets and lease liabilities for short-term leases and instead records them in a manner similar to operating leases under legacy leasing guidelines. A short-term lease is one with a maximum lease term of 12 months or fewer and does not include a purchase option that the lessee is reasonably certain to exercise. The Organization did not have any short-term leases during the years ended December 31, 2024 or 2023.

Property and equipment, net

The Organization's policy is to capitalize items with a cost greater than \$5,000 and an estimated useful life in excess of one year. Property and equipment are recorded at cost or, if donated, at the estimated fair value on the date of donation. Such donations are reported as contributions without donor restrictions unless the donor has restricted the donated asset to a specific purpose. Assets donated with explicit restrictions regarding their use and contributions of cash that must be used to acquire property and equipment are reported as restricted contributions. Absent donor stipulations regarding how long those donated assets must be maintained, the Organization reports expirations of donor restrictions when the donated or acquired assets are placed in service. Maintenance and repairs are charged to expense when incurred. Major improvements that extend the useful life of the asset are capitalized. Interest expense is capitalized for assets that require a period of time to prepare the assets for their intended use.

Depreciation and amortization of property and equipment is computed using the straight-line method over the following estimated useful lives:

Software	5 years
Furniture and equipment	5 years

Leasehold improvements are amortized over the shorter of the lease term or useful lives of the improvements.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Property and equipment, net (continued)

The Organization evaluates the recoverability of the carrying value of long-lived assets whenever events or circumstances indicate the carrying amount may not be recoverable. If a long-lived asset is tested for recoverability and the undiscounted estimated future cash flows expected to result from the use and eventual disposition of the asset is less than the carrying amount of the asset, the asset cost is adjusted to fair value and an impairment loss is recognized as the amount by which the carrying amount of a long-lived asset exceeds its fair value. No asset impairment was recognized during the years ended December 31, 2024 or 2023.

Revenue recognition

Contributions

Contributions, including unconditional promises to give, are recognized as revenues in the period the promise is received. Contributions that are promised in one year but are not expected to be collected until after the end of that year are discounted at an appropriate discount rate commensurate with the risks involved. Amortization of any such discounts is recorded as additional contribution revenue in accordance with donor-imposed restrictions, if any, on the contributions. An allowance for doubtful contributions receivable is provided based upon management's judgment including such factors as prior collection history, type of contribution and current aging of contributions receivable as necessary. The Organization considered all contributions receivable to be fully collectible at December 31, 2024 and 2023. Accordingly, no allowance for doubtful contributions receivable is recorded within the accompanying financial statements.

Conditional promises to give are not recognized until they become conditional, that is, when the barriers on which they depend are substantially overcome, and there is no longer a right of return of the asset or right of release from the obligation. Conditional contributions with donor stipulations which are satisfied in the period the contribution is received are recorded as revenue with donor restrictions and then released from restriction. The Organization had no conditional gifts as of December 31, 2024 or 2023.

Program service income

The Organization receives program service income based on the volume of transactions processed by a certain financial services provider. Revenue is recognized when earned in accordance with the specific terms of the agreement. The Organization uses the allowance method to account for program service income. The AECL related to the program service receivable is based on historical collection experience and expectations of future cash flows based on the evaluation of the outstanding receivables at the end of the year. Bad debt recoveries are included in income as realized. Management has determined that no AECL for the program service receivable was necessary at December 31, 2024 or 2023.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenue recognition (continued)

Software licenses

Revenue from the license of the Organization's software is recognized at the time that the Organization satisfies the performance obligations at the estimated transaction price or the amount to which the Organization expects to be entitled in exchange for providing services. The Organization contracts with a co-payments assistance foundation annually to provide these services. The annual base fee is fixed or determinable and is recognized ratably over the term of the contract. The additional subscription fee is earned after exceeding a determined usage volume and recognized ratably over the term of the contract. The Organization determined there were no price concessions and no variable considerations in the contract. Collectability is probable.

Contributed goods and services and in-kind contributions

Contributed goods are reflected as contributions in the accompanying statements of activities at their estimated fair values at the date of receipt. There were no contributed goods donated to the Organization during the years ended December 31, 2024 or 2023.

Contributed services are reflected in the financial statements at the fair value of the services received. Contributions of services are recognized if the services received (a) create or enhance nonfinancial assets or (b) require specialized skills that are provided by individuals possessing those skills and would typically need to be purchased if not provided by donation. The Organization received \$300,000 of contributed advertising services during the year ended December 31, 2024. The contributed services were valued at the rate of the advertiser providing the services. The contributed services were considered without donor restrictions. These amounts have been reported as contributions and community and education expenses on the accompanying statement of activities and statement of functional expenses, respectively, during the year ended December 31, 2024. No amounts have been recognized for contributed services in the accompanying statement of activities during the year ended December 31, 2023 because the criteria for recognition have not been satisfied.

Income taxes

The Organization is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and a similar provision of state law. However, the Organization is subject to federal income tax on any unrelated business taxable income.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Income taxes (continued)

U.S. GAAP requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Organization's tax returns to determine whether the tax positions are more likely than not of being sustained by the applicable tax authority. Tax positions not deemed to meet the more likely than not threshold would be recorded as a tax benefit or expense in the current year. Reconciliation is not provided herein, as the beginning and ending amounts of unrecognized benefits are zero, with no interim additions, reductions or settlements. The Organization is relying on its tax-exempt status and its adherence to all applicable laws and regulations to preserve that status. However, the conclusions regarding the uncertainty in income taxes will be subject to review and may be adjusted at a later date based on factors including, but not limited to, ongoing analysis of tax laws, regulations and interpretations thereof.

Advertising costs

The Organization expenses all advertising costs as incurred. Total advertising costs were \$33,196 and \$23,769 for the years ended December 31, 2024 and 2023, respectively, and are included in the accompanying statements of functional expenses.

Functional allocation of expenses

The costs of providing programs and other activities have been summarized on a functional basis in the accompanying statements of activities. The statements of functional expenses present the natural classification detail of expenses by function. Expenses are recorded as attributable to program services, management and general or fundraising whenever possible. However, certain categories of expenditures are attributable to more than one function, and therefore require allocation on a reasonable basis that is consistently applied (see Note 9). Expenses such as information technology, rent and utilities, telephone and internet and depreciation and amortization have been allocated based on the estimated square foot usage of the Organization's office space.

Retirement plan

The Organization offers a 403(b) retirement plan (the "Plan") that is available to all employees after meeting certain eligibility requirements and provides for contributions by the employees up to a certain percentage of their compensation. The Organization makes matching contributions up to a certain percentage of the employees' contributions. Organization contributions are voluntary and at the discretion of management. The Organization's matching contributions for the Plan for the years ended December 31, 2024 and 2023 were \$151,849 and \$97,248, respectively, which are included with payroll taxes in the accompanying statements of functional expenses.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

3. LIQUIDITY AND FUNDS AVAILABLE

The Organization monitors its liquidity in order to meet operating needs and other contractual commitments while maintaining sufficient resources to meet donor restrictions placed on contributed financial assets.

As part of the Organization's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities and other obligations come due.

The following quantitative disclosure describes financial assets that are available or expected to be available within one year of December 31 to fund general expenditures and obligations as they become due:

	2024	2023
Financial assets:		
Cash and cash equivalents	\$ 17,877,342	\$ 65,827,712
Accounts receivable	141,295	243,475
Contributions receivable	1,801,000	12,760,000
Program service receivable	512,865	467,672
Investments, at fair value	<u>194,869,073</u>	<u>137,105,474</u>
	<u>215,201,575</u>	<u>216,404,333</u>
Less amounts unavailable for general expenditure within one year due to:		
Investments with maturity dates exceeding one year	<u>(38,086,693)</u>	<u>(4,777,461)</u>
	<u>\$ 177,114,882</u>	<u>\$ 211,626,872</u>

At December 31, 2024 and 2023, \$96,042,063 and \$118,222,441, respectively, of net assets with donor restrictions are restricted for the primary program of the Organization and are considered available for general expenditure.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

4. INVESTMENTS, AT FAIR VALUE AND INVESTMENT INCOME, NET

Investments, at fair value consisted of the following:

	2024	2023
Money market mutual funds	\$ 95,394,482	\$ 99,659,100
Corporate bonds	87,976,795	29,100,708
Government and agency bonds	350,017	324,998
International bonds	5,553,269	2,770,235
Mortgage and asset backed bonds	304,710	395,227
Other fixed income bonds	3,956,590	4,105,012
Accrued interest	1,333,210	750,194
	\$ 194,869,073	\$ 137,105,474

Investment income, net consisted of the following:

	2024	2023
Interest and dividends	\$ 8,777,391	\$ 4,927,584
Net realized and unrealized gains on investments	1,238,215	1,290,651
Investment fees	(103,254)	(98,680)
	\$ 9,912,352	\$ 6,119,555

5. FAIR VALUE MEASUREMENTS

The following table sets forth by level, within the fair value hierarchy, the Organization's assets at fair value as of December 31, 2024:

	Level 1	Level 2	Level 3	Fair Value
Money market mutual funds	\$ 95,394,482	\$ -	\$ -	\$ 95,394,482
Corporate bonds	-	87,976,795	-	87,976,795
Government and agency bonds	-	350,017	-	350,017
International bonds	-	5,553,269	-	5,553,269
Mortgage and asset backed bonds	-	304,710	-	304,710
Other fixed income bonds	-	3,956,590	-	3,956,590
	\$ 95,394,482	\$ 98,141,381	\$ -	\$ 193,535,863

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

5. FAIR VALUE MEASUREMENTS (continued)

The following table sets forth by level, within the fair value hierarchy, the Organization's assets at fair value as of December 31, 2023:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Fair Value</u>
Money market mutual funds	\$ 99,659,100	\$ -	\$ -	\$ 99,659,100
Corporate bonds	-	29,100,708	-	29,100,708
Government and agency bonds	-	324,998	-	324,998
International bonds	-	2,770,235	-	2,770,235
Mortgage and asset backed bonds	-	395,227	-	395,227
Other fixed income bonds	-	4,105,012	-	4,105,012
	<u>\$ 99,659,100</u>	<u>\$ 36,696,180</u>	<u>\$ -</u>	<u>\$ 136,355,280</u>

6. PROPERTY AND EQUIPMENT, NET

Property and equipment, net consisted of the following:

	<u>2024</u>	<u>2023</u>
Software	\$ 64,640,498	\$ 63,910,942
Furniture and equipment	576,450	576,450
Leasehold improvements	<u>107,659</u>	<u>107,659</u>
	65,324,607	64,595,051
Less: accumulated depreciation and amortization	<u>(61,994,902)</u>	<u>(61,886,762)</u>
	<u>\$ 3,329,705</u>	<u>\$ 2,708,289</u>

Depreciation and amortization expense for the years ended December 31, 2024 and 2023, was \$108,140 and \$129,696, respectively.

7. NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions of \$96,042,063 and \$118,222,441 were available for assistance expenses for diseases as specified by donors at December 31, 2024 and 2023, respectively.

Net assets released from restriction totaled \$485,962,403 and \$399,840,236 during the years ended December 31, 2024 and 2023, respectively. Net assets were released from donor restrictions by incurring assistance expenses to satisfy the restricted purposes specified by donors.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

8. COMMITMENTS AND CONTINGENCIES

The Organization maintains operating leases for postage and mailing equipment and office space that expire in 2029 and 2028, respectively. At December 31, 2024, the operating lease right-of-use ("ROU") assets and operating lease liabilities were \$1,500,035 and \$1,698,020 respectively. At December 31, 2023, the operating lease ROU assets and operating lease liabilities were \$1,797,122 and \$2,004,633, respectively.

The Organization utilized the risk-free rate of return in calculating the discount on each of the leases based on the respective commencement date of the lease and the lease term.

Additional information related to leases during the year ended December 31 was as follows:

	2024	2023
Operating lease cost	\$ 297,087	\$ 290,385
Other information:		
Cash paid for amounts in the measurement of operating lease liabilities	\$ 326,565	\$ 324,173
Weighted average remaining lease term	4.81 years	5.81 years
Weighted average discount rate	1.58%	1.58%

The future maturities of the operating lease liabilities are as follows:

<u>Year ending December 31,</u>			
2025		\$	347,324
2026			357,999
2027			368,674
2028			374,341
2029			317,277
			1,765,615
Less: imputed interest			(67,595)
		<u>\$</u>	<u>1,698,020</u>

The Organization authorized an unrelated non-profit entity to process certain transactions using the Organization's third-party service provider. The Organization is liable to the third-party in the event of nonpayment by the unrelated non-profit entity. No such payments or collateral were required by the Organization during the years ended December 31, 2024 or 2023.

Chronic Disease Fund, Inc. dba Good Days
Notes to Financial Statements
December 31, 2024 and 2023

8. COMMITMENTS AND CONTINGENCIES (continued)

The Organization is exposed to various risks of loss from torts; theft of, damage to, and destruction of assets; business interruption; errors and omissions; employee injuries and illnesses; natural disasters; employee health, dental, and accident benefits; and acts of God. Commercial insurance coverage is purchased for claims arising from such matters. The Organization had not experienced significant claims that exceeded this commercial coverage during the years ended December 31, 2024 or 2023.

From time to time, the Organization is subject to certain claims and contingent liabilities that arise in the normal course of business. After consultation with legal counsel, management is of the opinion that liabilities, if any, arising from such litigation and examinations would not have a material effect on the Organization's financial position.

9. ALLOCATION OF JOINT COSTS

For the years ended December 31, 2024 and 2023, the Organization conducted activities that included requests for contributions, as well as program and management and general components. Those activities included the annual educational conference. The cost of conducting those activities included joint costs, which are not specifically attributable to particular components of the activities. Joint costs totaled \$929,299 and \$921,207 for the years ended December 31, 2024 and 2023, respectively, and are included with conferences expenses on the accompanying statements of functional expenses.

Joint costs were allocated as follows:

	2024	2023
Fundraising	\$ 65,051	\$ 64,485
Program services	334,547	331,634
Management and general	529,701	525,088
	\$ 929,299	\$ 921,207

10. CONCENTRATIONS

For the year ended December 31, 2024, one donor contributed approximately 91% of total contributions. For the year ended December 31, 2023, one donor contributed approximately 94% of total contributions. Contributions receivable as of December 31, 2024 were outstanding from two donors. Contributions receivable as of December 31, 2023 were outstanding from four donors. The contributions receivable for both years were fully collected subsequent to year-end.

11. SUBSEQUENT EVENTS

Management has evaluated subsequent events through June 13, 2025, the date the financial statements were available to be issued. No subsequent events were identified that would have a material impact on the presentation of the Organization's financial statements.